Apimeds Pharmaceuticals US, Inc. (APUS) Ratios
Apimeds Pharmaceuticals US, Inc. Ratios
APUS's free cash flow for Q2 2026 was $-6.18M. For the 2026 fiscal year, APUS's free cash flow was decreased by $-4.00 and operating cash flow was $-6.18M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 1.31 | 0.01 | 3.42 | 0.02 | 16.16 |
| Quick Ratio | 1.31 | 0.01 | 3.42 | 0.02 | 16.16 |
| Cash Ratio | 0.15 | 0.00 | 3.33 | 0.02 | 16.09 |
| Solvency Ratio | -0.55 | -1.01 | -1.99 | -0.93 | -2.50 |
| Operating Cash Flow Ratio | -0.83 | -0.72 | -5.09 | -1.40 | -77.27 |
| Short-Term Operating Cash Flow Coverage | -1.18 | -2.93 | 0.00 | -1.72 | 0.00 |
| Net Current Asset Value | $ 3.15M | $ -1.36M | $ 31.87K | $ -713.61K | $ -238.48K |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.05 | 45.71 | 0.63 | 106.95 | 2.32 |
| Debt-to-Equity Ratio | 0.05 | -0.44 | 8.37 | -0.92 | -1.68 |
| Debt-to-Capital Ratio | 0.05 | -0.78 | 0.89 | -12.31 | 2.48 |
| Long-Term Debt-to-Capital Ratio | 0.00 | -0.34 | 0.89 | -1.28 | 2.48 |
| Financial Leverage Ratio | 1.07 | -0.01 | 13.24 | -0.01 | -0.72 |
| Debt Service Coverage Ratio | -0.73 | -3.46 | -19.43 | -2.21 | -151.26 |
| Interest Coverage Ratio | -42.09 | -10.83 | -19.63 | -21.95 | -151.26 |
| Debt to Market Cap | 0.43 | 0.24 | 0.01 | 0.03 | 0.02 |
| Interest Debt Per Share | 7.39 | 0.62 | 0.03 | 0.06 | 0.04 |
| Net Debt to EBITDA | -1.07 | -0.47 | 0.19 | -1.02 | -0.22 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBIT Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBITDA Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Pretax Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 50.38% | 109.01% | 104.05% | 104.56% | 100.66% |
| Return on Assets (ROA) | -3.66% | -10645.55% | -184.25% | -10835.62% | -596.06% |
| Return on Equity (ROE) | -3.91% | 102.35% | -2440.13% | 93.70% | 430.32% |
| Return on Capital Employed (ROCE) | -7.76% | 126.09% | -250.18% | 203.93% | -631.20% |
| Return on Invested Capital (ROIC) | -7.39% | 167.49% | -250.18% | 1193.02% | -631.20% |
| Return on Tangible Assets | -3.66% | -10645.55% | -184.25% | -10835.62% | -596.06% |
| Earnings Yield | -33.63% | -54.81% | -3.07% | -2.64% | -4.05% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -58763.91 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 58763.91 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -8.20 | -0.64 | -0.05 | -0.04 | -0.07 |
| Free Cash Flow Per Share | -8.26 | -0.64 | -0.05 | -0.04 | -0.07 |
| Dividend Paid and CapEx Coverage Ratio | -155.68 | 0.00 | 0.00 | 0.00 | 0.00 |
| Capital Expenditure Coverage Ratio | -155.68 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cash Flow Coverage Ratio | -1.15 | -1.23 | -2.35 | -0.68 | -2.06 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow Yield | -50.34% | -28.93% | -2.48% | -1.77% | -3.25% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -2.98 | -1.83 | -32.61 | -37.93 | -24.71 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | 0.12 | -1.87 | 795.68 | -35.54 | -106.34 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -1.99 | -3.46 | -40.39 | -56.58 | -30.81 |
| Price-to-Operating Cash Flow Ratio | -2.00 | -3.46 | -40.39 | -56.58 | -30.81 |
| Price-to-Earnings Growth (PEG) Ratio | 0.06 | -0.02 | -1.99 | 1.09 | 0.00 |
| Enterprise Value Multiple | -4.20 | -2.46 | -34.09 | -40.68 | -25.10 |
| Enterprise Value | 23.97M | 3.13M | 25.22M | 26.01M | 25.59M |
| EV to EBITDA | -4.20 | -2.46 | -34.09 | -40.68 | -25.10 |
| EV to Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EV to Free Cash Flow | -2.67 | -4.27 | -40.17 | -58.04 | -31.09 |
| EV to Operating Cash Flow | -2.69 | -4.27 | -40.17 | -58.04 | -31.09 |
| Tangible Book Value Per Share | 140.92 | -1.18 | 0.00 | -0.06 | -0.02 |
| Shareholders’ Equity Per Share | 140.92 | -1.18 | 0.00 | -0.06 | -0.02 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -5.51 | -1.21 | -0.07 | -0.06 | -0.09 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.05 | 1.09 | 1.05 | 1.05 | 1.01 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 1.49 | 0.53 | 0.81 | 0.67 | 0.80 |
Currency in USD